So how can we tell how much of the other key milestone to spend the $6 million on CF33 Research and Development by 8th July 2021 has been done, as the dosing first patient milestone in a Phase 1 trial depends upon FDA IND approval.
Can see that received FDA guidance in August 2020 from pre IND meeting, but nothing further such as other pre clinical or toxicity testing has been mentioned that is underway.
If total R & D for 2020 year was $7million.
would think more than 3/4 world be from current ongoing Bvax and HerVax trials and bit towards the PD1-VAX that started end of 2020.
Ann: Half Yearly Report and Accounts, page-13
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $505.0M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.1¢ | 6.8¢ | $1.427M | 20.55M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 57517 | 6.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.0¢ | 667419 | 9 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.9¢ |
Change
0.000 ( 0.29 %) |
||||
| Open | High | Low | Volume | ||
| 6.9¢ | 7.1¢ | 6.8¢ | 7149293 | ||
| Last updated 15.59pm 21/05/2024 ? | |||||
| IMU (ASX) Chart |